Trial Profile
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 09 Apr 2020 Planned primary completion date changed from 15 Mar 2020 to 15 Mar 2021.
- 25 Oct 2019 Primary endpoint (Progression-free survival Phase III) has been met, according to the results published in the Journal of Clinical Oncology
- 25 Oct 2019 Results (n=182) assessing efficacy of Lenalidomide in patients with Smoldering Multiple Myeloma published in the Journal of Clinical Oncology